BioSpace News Archive

The U.S. Food and Drug Administration today announced it has authorized the marketing of two new tobacco products manufactured by 22nd Century Group Inc. – Moonlight and Moonlight Menthol, which are combusted, filtered cigarettes that contain a reduced amount of nicotine compared to typical commercial cigarettes.

Hospitals participating in the 340B drug pricing program are reimbursed for physician-administered medicines at a rate that is on average three times what they paid to acquire the medicine, according to a new analysis conducted by Milliman and commissioned by the Pharmaceutical Research and Manufacturers of America.

ARK Crystal LLC, today announced in partnership with Torus Tech LLC and the Energy Medicine Research Institute, results of a single blind human placebo controlled clinical study which examined the efficacy of the PGQMEM (Precision Geometric Quartz modulated electromagnetically, commercially known as ARK crystals) crystal to improve several athletic outcome measures.

The Pharmacy Technician Certification Board (PTCB) has awarded grants to state pharmacy associations in Arizona, Connecticut, and Massachusetts to support projects to advance medication safety and the role of pharmacy technicians, including programs to address the opioid abuse crisis.

Kelyniam Global (OTC:KLYG), a maker of custom craniomaxilofacial (CMF) implants, announced today that the company has signed a distribution agreement with SurgicalOne, a leading surgical specialty distribution company covering 10 States.

Biotech Leadership Consulting, LLC provides management consulting on bringing diverse experts together into a high performing, cross functional development team despite disciplinary, geographic, organizational or cultural barriers.

Achieve Life Sciences, Inc. announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Slated to open in the first quarter of 2020, the 36,000 square foot pharmacy will dispense Remedi’s proprietary dispensing system, PAXIT®, and will eventually employ more than 200 individuals.

Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $1.10 per share and a five-year term.

EnviroLogix Inc. offers first lateral flow test strip for the detection and quantification of aflatoxin and fumonisin in masa flour